Company Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 52.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $80.28M (+15.8% YoY); net profit $-38.83M.
- Trailing 12 Months Year-on-year growth — revenue -4.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 52.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 52.19% |
| 1 Year: | -4.50% |
Stock Price Performance
| 1 Year: | -43.34% |
| 6 Months: | -6.20% |
| 3 Months: | -2.34% |
| 1 Month: | -4.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)60.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 52.2% over 5 years.
CONS
- Trading 54.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TELA TELA Bio, Inc. PHARMA | 0.83 | -1.08 | $37.47M | 0.00% | -53.21% | - | 52.19% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21M | 3.31M | 3.30M | 3.97M | 3.73M | 3.51M | 5.31M | 5.88M | 7.56M | 7.65M | 8.23M | 10.41M | 11.16M | 11.91M | 14.49M | 15.05M | 16.60M | 16.09M | 18.96M | - | 18.52M | 20.20M | 20.69M | 20.87M | 19.06M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.01M | 6.09M | 6.72M | 7.11M | 6.54M |
| Gross Profit | 1.37M | 1.80M | 1.91M | 2.60M | 2.20M | 2.08M | 3.29M | 3.46M | 5.09M | 4.60M | 5.00M | 6.55M | 7.32M | 7.90M | 10.20M | 10.39M | 11.34M | 11.07M | 12.86M | - | 12.51M | 14.11M | 13.97M | 13.76M | 12.52M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.98M | 23.19M | 21.52M | 20.40M | 23.05M |
| Operating Income | -2.52M | -5.18M | -4.30M | -3.86M | -6.50M | -5.17M | -6.86M | -7.27M | -7.31M | -7.22M | -9.84M | -10.24M | -9.49M | -11.25M | -10.36M | -10.18M | -4.83M | -11.57M | -9.37M | - | -10.47M | -9.08M | -7.55M | -6.65M | -10.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.73M | -8.43M | -7.15M | -7.03M | -9.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22M | 1.19M | 1.20M | 1.64M | 2.05M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.21M | -9.89M | -8.60M | -8.90M | -12.21M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.00K | 33.00K | 0 | 145.00K | 60.00K |
| Net Income | -2.81M | -5.97M | -5.26M | -4.67M | -7.22M | -6.08M | -7.70M | -8.14M | -8.26M | -8.27M | -10.86M | -12.74M | -10.71M | -12.03M | -10.79M | -10.96M | -5.66M | -12.60M | -10.37M | - | -11.26M | -9.92M | -8.60M | -9.04M | -12.27M |
| Diluted EPS | - | - | - | - | - | - | - | -0.56 | -0.57 | -0.57 | -0.75 | -0.88 | -0.64 | -0.63 | -0.46 | -0.45 | -0.23 | -0.51 | -0.42 | - | -0.25 | -0.22 | -0.19 | -0.17 | -0.21 |
| R&D Expense | 1.04M | 1.66M | 1.05M | 516.00K | 912.00K | 979.00K | 1.20M | 1.68M | 1.93M | 1.41M | 2.01M | 2.10M | 2.10M | 2.05M | 2.51M | 2.37M | 2.39M | 2.32M | 2.07M | - | 2.54M | 2.20M | 2.35M | - | 2.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.25M | 8.27M | 15.45M | 18.21M | - | 41.42M | 58.45M | 69.30M | 80.28M |
| Cost of Revenue | - | - | - | - | - | 14.37M | 18.34M | 22.81M | 25.93M |
| Gross Profit | 2.53M | 2.94M | 9.27M | 11.23M | - | 27.04M | 40.11M | 46.49M | 54.34M |
| Operating Expenses | - | - | - | - | - | 66.05M | 84.19M | 88.18M | 88.10M |
| Operating Income | -16.92M | -17.78M | -19.16M | -25.27M | - | -39.01M | -44.08M | -41.70M | -33.76M |
| EBITDA | - | - | - | - | - | -39.06M | -40.63M | -31.68M | -32.35M |
| Interest Expense | - | - | - | - | - | 4.05M | 5.22M | 5.29M | 5.25M |
| Pretax Income | - | - | - | - | - | -44.30M | -46.66M | -37.98M | -38.60M |
| Tax Provision | - | - | - | - | - | 0 | 0 | -144.00K | 230.00K |
| Net Income | -21.33M | -21.09M | -22.43M | -28.79M | - | -44.30M | -46.66M | -37.84M | -38.83M |
| Diluted EPS | - | - | -17.10 | -2.23 | - | -2.72 | -2.04 | -1.33 | -0.83 |
| R&D Expense | 5.79M | 4.34M | 4.15M | 4.25M | 6.74M | 8.94M | 9.62M | 8.81M | 9.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.23M | 67.92M | 86.46M | - | 67.86M | 78.05M | 86.57M | 81.42M |
| Current Assets | - | - | - | - | - | - | 62.45M | 71.73M | 78.07M | 75.58M |
| Cash & Equivalents | - | - | 17.28M | 45.30M | 74.39M | - | 42.02M | 46.73M | 52.67M | 50.84M |
| Inventory | - | - | - | - | - | - | 11.79M | 13.16M | 12.78M | 11.02M |
| Receivables | - | - | - | - | - | - | 6.62M | 9.74M | 10.10M | 10.35M |
| Total Liabilities | - | - | 40.94M | 36.96M | 37.43M | - | 53.55M | 59.17M | 58.11M | 75.11M |
| Current Liabilities | - | - | 9.56M | 6.71M | 6.61M | - | 12.40M | 16.97M | 15.60M | 17.98M |
| Long Term Debt | - | - | - | 30.24M | 30.83M | - | 39.92M | 40.52M | 41.12M | 55.65M |
| Total Debt | - | - | - | - | - | - | 40.26M | 41.08M | 41.67M | 56.18M |
| Total Equity | -81.17M | -108.17M | -137.86M | 30.96M | 49.03M | - | 14.30M | 18.88M | 28.46M | 6.31M |
| Shares Outstanding | - | - | - | - | - | - | 19.17M | 24.49M | 39.40M | 44.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.37M | -19.92M | -25.52M | -24.46M | - | -40.75M | -40.86M | -41.59M | -28.22M |
| Investing Cash Flow | -101.00K | -1.56M | -11.98M | 9.12M | - | -1.87M | -599.00K | 4.45M | 846.00K |
| Financing Cash Flow | 26.34M | 27.41M | 65.53M | 44.41M | - | 40.85M | 46.27M | 43.06M | 25.75M |
| Capital Expenditure | -114.00K | -62.00K | -197.00K | -167.00K | - | -1.87M | -611.00K | -989.00K | -448.00K |
| Free Cash Flow | -16.48M | -19.99M | -25.72M | -24.62M | - | -42.62M | -41.47M | -42.58M | -28.67M |
| Net Change in Cash | - | - | - | - | - | -1.77M | 4.81M | 5.91M | -1.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 59.6% | 35.6% | 60.0% | 61.7% | - | 65.3% | 68.6% | 67.1% | 67.7% |
| Operating Margin % | -398.7% | -214.9% | -124.1% | -138.8% | - | -94.2% | -75.4% | -60.2% | -42.0% |
| Net Margin % | -502.6% | -254.9% | -145.2% | -158.1% | - | -106.9% | -79.8% | -54.6% | -48.4% |
| ROE % | 19.7% | 15.3% | -72.4% | -58.7% | - | -309.7% | -247.1% | -133.0% | -615.1% |
| ROCE % | - | -100.6% | -31.3% | -31.7% | - | -70.3% | -72.2% | -58.7% | -53.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Essex Woodlands Management Inc. | 17.09% | 7.71M | $9.64M |
| 2 | Nantahala Capital Management, LLC | 13.06% | 5.89M | $7.37M |
| 3 | Stonepine Capital Management, LLC | 5.90% | 2.66M | $3.33M |
| 4 | SilverArc Capital Management, LLC | 4.73% | 2.14M | $2.67M |
| 5 | Vanguard Capital Management LLC | 3.47% | 1.57M | $1.96M |
| 6 | DAFNA Capital Management, LLC | 3.19% | 1.44M | $1.80M |
| 7 | Perkins Capital Management, Inc. | 3.05% | 1.38M | $1.72M |
| 8 | Sio Capital Management, LLC | 1.41% | 636.30K | $795.38K |
| 9 | Wealthtrust Axiom, LLC | 1.01% | 457.73K | $572.17K |
| 10 | Geode Capital Management, LLC | 0.86% | 389.22K | $486.53K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TELA
Reverse split of up to 1-for-15 heads to a vote at TELA Bio (NASDAQ: TELA) after Nasdaq bid-price warning - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNd2loQmtUMXRsWHB4RDVnRzFta3VRNklRMG45NDhxZlZqTmhqRWlXNFViYTh1MzliWG1qMk1RelVwbFRva3JRZEI4bHBtVWpKa2lxUklBR0prRVFYdkVxVVBXbWpYeDJIbXZDdVdSMDJUUFRMMGE2ODRMMTM1VGdMTm5WMEtDbHZwT3BDR3…
Tela Bio CEO Heather Getz buys $8,311 in company stock By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNck1wZzlBc1FPeXJnT1VYZTJPR2VodDdzWnctSFdpMXRfRWprQ195LWJpNUZ5NU51VEc1bk8xSTRIM05UU05iRWktUy1kM0VldzNQanVBQlZkUEp4b2l2SmJPdlZVUm1rY0ZSYmU4SjVCWXpSLUVTMWtOOGFraHMweHlSSzd6RGdseHZVSU…
Insider Purchase: Chief Executive Officer of $TELA Buys 15,000 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQZG5OdzY5ZS12NHlHcVVJLTAtQjFuX0RNUUlMTU50ZEtmZ0tLcjRmd2tUY2I1WFd6MTRNYUJROHZmOVRIMlJISUxiNmJfRlZjcm5GUk96Z040RGR3RzhaZDBQck01ZWZnVkJVT2QwNFpKTTJHM3RzeW1TSWRGclhvNDJJcEljTE1YakpXcz…
Tesla Stock Tumbles After Big Earnings Miss - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPV0VOLTlrMEVHc3VPb1VVaVVYVEhuOGh2WG14ZlVrUFZ3bkdoc3RHTzFWM1ItTUlGejE4VnNKYlh4UnJMSHhURFh3Rjk2aVNueC1vd3dyQjhHcjg1SWlqV3BSQlVuRlh2bXFHLTEwSkxmbzNrTWNzWHlGU1h1WkllVEJHMGRJUmk5OWZ6bm…
TELA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5DY3ZOcjZpd3FTYUpnamwyRVZLWjloN1lFbmduaGJCUWVaZWRTclVwR1YtcEhOekZkUUJRdkk2ZllDbGZpcERVMWwwM0RCdlFGSFhTb2drbkZSdTUwR0ZsQ29SWmxZWmg2b0psRnNTeWxiaWgzQ1RqSzdn?oc=5" target="_blank">TEL…
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQQXp5WnhpUElGSVRlUU5STWVIN0t2YkRfdGNIOE5zelVfRzJTSXc3M3NiaU5IMnlpSXBXZy1Jdk1fdmhYMTRpcDdUQTgtanRYTlprSXNsaDFTSm02TDg0ZGRRN3VObkQ3SVV4YnRfMjM5RXM1UlRJd1k3UFRrUzV3TTdEZi1hY0czMDNROU…
TELA — Frequently Asked Questions
What is the current share price of TELA Bio, Inc. (TELA)?
As of 2026-09-19 21:16 PDT, TELA Bio, Inc. (TELA) trades at $0.83 on NasdaqGM. Its 52-week range is $0.56 to $1.83.
What is the market capitalisation of TELA?
TELA Bio, Inc. (TELA) has a market capitalisation of $37.47M on NasdaqGM.
What is the P/E ratio of TELA?
TELA trades at a trailing price-to-earnings (P/E) ratio of -1.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -3.53.
Is TELA a good stock to buy?
This page provides a data-driven analysis of TELA Bio, Inc. (TELA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.